Received May 24, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | NT357 | — |
Shingrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 76-year-old female patient who received Herpes zoster (Shingrix) (batch number NT357, expiry date 12-MAY-2028) for prophylaxis. Previously administered products included Shingrix (received first dose of Shingrix on 30-SEP-2023, ZS3D7 with expiry 08-OCT-2024). On 11-MAR-2026, the patient received the 2nd dose of Shingrix. On 11-MAR-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 18-MAY-2026 Healthcare provider wanted to know how to proceed with a patient that received the second dose on 11-MAR-2026 after receiving the first one on 30-SEP-2023.